<DOC>
	<DOCNO>NCT00812786</DOCNO>
	<brief_summary>The main objective develop pharmacokinetic method individual dose adjustment global immunosuppressive treatment ( cyclosporine , tacrolimus , mycophenolate mofetil everolimus , take account pharmacokinetic interaction ) , order optimise efficiency reduce potentially severe side effect drug . Forty five heart-transplant patient include phase IV study obtain minimum 10 patient treated tacrolimus-mycophenolate , 10 cyclosporine-mycophenolate 20 everolimus-cyclosporine . Ten 11 blood sample collect within 8 12 hour post-dose patient immunosuppressive drug concentration measure LC-MS/MS . The pharmacokinetic model Bayesian estimator thus develop provide tool individual dose adjustment immunosuppressive drug simultaneously , different post-transplant period , use area concentration-time curve ( AUC ) estimate use limited number time-points ( 2 3 ) .</brief_summary>
	<brief_title>Pharmacokinetics Immunosuppressive Drugs Heart Transplant Patients</brief_title>
	<detailed_description>For heart transplant patient , 10 11 blood sample ( 5 mL ) collect follow dose immunosuppressive drug ( T0 , T20 ' , T40 ' , T60 ' , T90 ' , T2h , T3h , T4h , T6h , T8h T10h + T12h inpatient ) , several post-transplant period ( 7 15 day , 1 month , 3 month 1 year transplantation ) . One blood sample take D7-14 pharmacogenetic analysis .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patient receive heart transplant ( exclusively ) less 2 week inclusion date plan receive within day follow inclusion . Patient least 18 year old , male female . Patient treat one follow combination : cyclosporinemycophenolate , tacrolimusmycophenolate everolimus `` lowdose '' cyclosporine least 3 day , least 24 hour oral route time first sample day ( 7 15 day posttransplant ) . Patient include another study , particular therapeutic trial ( e.g . comparison drug combination ) . Patient give write informed consent his/her participation trial . Patients disagreement present trial . Patients suffer neuropsychic problem , make unable wellunderstand protocol give reliable consent . Patients previous heart solid organ transplantation . Patients double transplantation ( heartlung , heartkidney heartliver ) Patients still intubate ventilate 15 day posttransplant . Patients anaemia Day 7 15 , characterize hematocrit &lt; 30 % haemoglobin &lt; 9 g/dl .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>heart transplantation</keyword>
	<keyword>immunosuppressive drug</keyword>
	<keyword>individual dose adjustment</keyword>
	<keyword>harmacokinetics</keyword>
	<keyword>model</keyword>
</DOC>